KR102075694B1 - Composition for preventing or treating hearing loss comprising Syzygium cumini extracts - Google Patents
Composition for preventing or treating hearing loss comprising Syzygium cumini extracts Download PDFInfo
- Publication number
- KR102075694B1 KR102075694B1 KR1020170174390A KR20170174390A KR102075694B1 KR 102075694 B1 KR102075694 B1 KR 102075694B1 KR 1020170174390 A KR1020170174390 A KR 1020170174390A KR 20170174390 A KR20170174390 A KR 20170174390A KR 102075694 B1 KR102075694 B1 KR 102075694B1
- Authority
- KR
- South Korea
- Prior art keywords
- hearing loss
- cumini
- extract
- syzygium
- composition
- Prior art date
Links
- 206010011878 Deafness Diseases 0.000 title claims abstract description 76
- 208000016354 hearing loss disease Diseases 0.000 title claims abstract description 76
- 231100000888 hearing loss Toxicity 0.000 title claims abstract description 66
- 230000010370 hearing loss Effects 0.000 title claims abstract description 66
- 235000012097 Eugenia cumini Nutrition 0.000 title claims abstract description 43
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 244000078732 Syzygium cumini Species 0.000 title claims abstract 4
- 239000000284 extract Substances 0.000 title abstract description 48
- 238000011282 treatment Methods 0.000 claims abstract description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
- 230000002265 prevention Effects 0.000 claims abstract description 12
- 235000013305 food Nutrition 0.000 claims description 16
- 239000004480 active ingredient Substances 0.000 claims description 8
- 231100000331 toxic Toxicity 0.000 claims description 8
- 230000002588 toxic effect Effects 0.000 claims description 8
- 239000000401 methanolic extract Substances 0.000 claims description 6
- 206010011891 Deafness neurosensory Diseases 0.000 claims description 5
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 claims description 5
- 231100000879 sensorineural hearing loss Toxicity 0.000 claims description 5
- 208000023573 sensorineural hearing loss disease Diseases 0.000 claims description 5
- 230000003612 virological effect Effects 0.000 claims description 5
- 208000000781 Conductive Hearing Loss Diseases 0.000 claims description 3
- 206010010280 Conductive deafness Diseases 0.000 claims description 3
- 206010061373 Sudden Hearing Loss Diseases 0.000 claims description 3
- 208000023563 conductive hearing loss disease Diseases 0.000 claims description 3
- 230000000472 traumatic effect Effects 0.000 claims description 3
- 206010011903 Deafness traumatic Diseases 0.000 claims 2
- 208000002946 Noise-Induced Hearing Loss Diseases 0.000 claims 2
- 210000002768 hair cell Anatomy 0.000 abstract description 11
- 230000036541 health Effects 0.000 abstract description 11
- 231100000895 deafness Toxicity 0.000 abstract description 10
- 235000013376 functional food Nutrition 0.000 abstract description 7
- 230000005779 cell damage Effects 0.000 abstract description 5
- 230000006872 improvement Effects 0.000 abstract description 4
- 208000037887 cell injury Diseases 0.000 abstract description 3
- 244000060474 Eugenia jambolana Species 0.000 description 38
- 238000000605 extraction Methods 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 244000045719 Syzygium Species 0.000 description 12
- 235000012096 Syzygium samarangense Nutrition 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 229940079593 drug Drugs 0.000 description 10
- 238000009472 formulation Methods 0.000 description 9
- 206010033078 Otitis media Diseases 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 229930193140 Neomycin Natural products 0.000 description 7
- 208000005141 Otitis Diseases 0.000 description 7
- 208000019258 ear infection Diseases 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 229960004927 neomycin Drugs 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 238000007796 conventional method Methods 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 235000013373 food additive Nutrition 0.000 description 4
- 239000002778 food additive Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 241000252212 Danio rerio Species 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 229940124599 anti-inflammatory drug Drugs 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 210000003027 ear inner Anatomy 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000020510 functional beverage Nutrition 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- -1 sibeomycin Chemical compound 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 244000234162 Eugenia cumini Species 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 229960004821 amikacin Drugs 0.000 description 2
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 2
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000748 compression moulding Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 206010033072 otitis externa Diseases 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000000270 postfertilization Effects 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 210000003454 tympanic membrane Anatomy 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 244000304337 Cuminum cyminum Species 0.000 description 1
- 235000007129 Cuminum cyminum Nutrition 0.000 description 1
- 235000007877 Diospyros australis Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000219926 Myrtaceae Species 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036626 Presbyacusis Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 235000010875 Prunus nigra Nutrition 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- URWAJWIAIPFPJE-UHFFFAOYSA-N Rickamicin Natural products O1CC(O)(C)C(NC)C(O)C1OC1C(O)C(OC2C(CC=C(CN)O2)N)C(N)CC1N URWAJWIAIPFPJE-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 206010047482 Viral upper respiratory tract infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 235000018288 Vitex doniana Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229940126574 aminoglycoside antibiotic Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 210000003477 cochlea Anatomy 0.000 description 1
- 210000000860 cochlear nerve Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000027326 copulation Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229960003807 dibekacin Drugs 0.000 description 1
- JJCQSGDBDPYCEO-XVZSLQNASA-N dibekacin Chemical compound O1[C@H](CN)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N JJCQSGDBDPYCEO-XVZSLQNASA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 208000032625 disorder of ear Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000000613 ear canal Anatomy 0.000 description 1
- 210000000883 ear external Anatomy 0.000 description 1
- 208000007176 earache Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 210000002388 eustachian tube Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000022760 infectious otitis media Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 235000019462 natural additive Nutrition 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229960000808 netilmicin Drugs 0.000 description 1
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- URWAJWIAIPFPJE-YFMIWBNJSA-N sisomycin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC=C(CN)O2)N)[C@@H](N)C[C@H]1N URWAJWIAIPFPJE-YFMIWBNJSA-N 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229940072040 tricaine Drugs 0.000 description 1
- FQZJYWMRQDKBQN-UHFFFAOYSA-N tricaine methanesulfonate Chemical compound CS([O-])(=O)=O.CCOC(=O)C1=CC=CC([NH3+])=C1 FQZJYWMRQDKBQN-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000001720 vestibular Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Botany (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Medical Informatics (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 시지지움 큐미니 (Syzygium cumini) 추출물을 포함하는 난청의 예방, 개선 또는 치료용 조성물을 제공한다.
본 발명에 따른 조성물은 난청으로 인한 청력 역치의 상승과 유모세포 손상을 효과적으로 억제시킴으로써 난청을 억제할 수 있어 난청의 예방 또는 치료에 유용하여, 약학 조성물 또는 건강기능식품으로써 유용하게 사용될 수 있다. The present invention provides a composition for the prevention, improvement or treatment of deafness, including Syzygium cumini extract.
The composition according to the present invention can suppress hearing loss by effectively suppressing the increase of hearing threshold and hair cell damage due to hearing loss, and thus useful for the prevention or treatment of hearing loss, and can be useful as a pharmaceutical composition or health functional food.
Description
본 발명은 시지지움 큐미니 (Syzygium cumini) 추출물을 포함하는 난청의 예방 또는 치료용 조성물에 관한 것이다. The present invention relates to a composition for the prevention or treatment of hearing loss, comprising Syzygium cumini extract.
귀에 연관된 질환들에 대한 연구 개발은 세균성 외이염, 악성 이염, 균성 외이염, 이진균증, 중이염, 또는 내이염 등의 염증에 의해 유발되는 질환들에 대한 것이 대다수였으며, 이와 관련된 치료제들의 기술 개발이 주로 이루어졌다. The research and development of diseases related to the ear were mostly for diseases caused by inflammation such as bacterial otitis media, malignant otitis, fungal otitis, binary fungal infection, otitis media, or otitis media, and the development of technologies related to the treatments were mainly made. .
질환을 구체적으로 살펴보면, 외이염 (외부 귀 감염)은 바깥 귀 및 외이도의 염증이다. 외이염은 인간에서 귀앓이의 통상적인 원인이며, 염증은 균성, 바이러스성 또는 세균성 유기체가 원인일 수 있다. 외이도 피부가 흔히 부풀어 오르고, 고통스러우며, 만지면 아플 수 있다. 중이염 (중간 귀 감염)은 고막과 유스타티오관을 포함하는 안쪽 귀 사이 부위에서 일어난다. 중이염은 어린이에게서 매우 흔한데, 평균적으로 유아는 매년 2-3차례 경험하며, 통상 바이러스성 상기도 감염 (URI), 및 대부분 감기와 수반된다. 매우 흔한 감기 증상의 원인이 되는 리노바이러스(rhinoviruses) 및 아데노바이러스는 안쪽 귀안에 팽창과 충혈을 일으킨다. 또한 중이염은 또한 다양한 세균 및 기타 바이러스에 의해 흔히 일어난다.Looking specifically at the disease, otitis externa (external ear infection) is inflammation of the outer ear and ear canal. Otitis is a common cause of earaches in humans, and inflammation may be caused by a fungal, viral or bacterial organism. The external auditory meatus is often swollen, painful, and painful if touched. Otitis media (middle ear infection) occurs at the site between the tympanic membrane and the inner ear, which contains the eustachian tube. Otitis media is very common in children, on average infants experience 2-3 times a year, usually accompanied by viral upper respiratory tract infection (URI), and mostly colds. Rhinoviruses and adenoviruses, the most common cause of cold symptoms, cause swelling and hyperemia in the inner ear. Otitis media is also commonly caused by various bacteria and other viruses.
위와 같은 귀와 관련된 질환의 대부분의 치료는 약제로써 항생제, 항염증제 등을 이용하는 것들이었고, 현재까지도 대부분 치료제는 항생제 또는 항염증제를 기반으로 하는 치료 방법에 기반을 둔 것이다.Most of the treatment of the ear-related diseases, such as those using antibiotics, anti-inflammatory drugs, etc., and to date, most of the therapeutic drugs are based on antibiotics or anti-inflammatory drugs.
그러나, 현대 사회에서는 소음 노출의 증가 및 인구의 고령화 등으로 인하여 위와 같은 염증 기반의 귀 관련 질환 보다는, 세포나 신경 손상에 의한 난청과 관련된 문제가 크게 대두되고 있다. 더욱이, 일반인들도 대부분 세균성 외이염, 악성 이염, 균성 외이염, 이진균증, 중이염, 또는 내이염 등의 염증이 원인이 되는 귀 관련 질환과 세포나 신경 손상에 의한 난청의 질환 차이를 구별할 수 있을 정도로, 난청은 현대 사회에 발병률이 높고 널리 알려진 질환 중 하나이다. 이러한 세포나 신경 손상에 의한 난청은 소음이나 노화 등의 원인 외에 이독성 약물, 신경계 독성 화학물질, 바이러스성, 유전 등이 있으며 원인 불명인 경우도 있다. However, due to the increase in noise exposure and the aging of the population, the problems related to hearing loss due to cellular or nerve damage are emerging, rather than the above-described inflammatory-based ear-related diseases. Moreover, most people can distinguish ear-related diseases caused by inflammation such as bacterial otitis, malignant otitis, fungal otitis, binary fungal infection, otitis media, or otitis and hearing loss caused by cellular or nerve damage. Hearing loss is one of the most prevalent and widely known diseases in modern society. Hearing loss caused by damage to cells or nerves may be caused by noise, aging, etc., as well as by toxic drugs, toxic chemicals in the nervous system, viral diseases, and genetics.
위 난청의 치료를 위해서 다수의 전문의 및 의약 업계 관련 종사자들은 여전히 기존의 항생제 또는 항염증제에 기반을 둔 치료제로써 위 질환의 치료를 목적하고 있으나, 이는 난청과 관련하여 적합한 치료제로 이용될 수 없다. 위와 같은 기존 치료제의 이용은 첫 번째로 난청과 관련된 치료제가 알려진 것이 없기 때문이며, 두 번째로 난청에 대한 치료법에 대해 다수의 전문의 및 의약 업계 관련 종사자들이 명확히 인지하지 못하기 때문이다. 이러한 문제점에 의해 난청의 치료를 적절히 수행하지 못하는 문제점이 지속적으로 발생하고 있다. For the treatment of gastric deafness, a number of specialists and workers in the pharmaceutical industry are still aiming to treat the above diseases with antimicrobial or anti-inflammatory drugs based on existing antibiotics, but they cannot be used as a suitable treatment for hearing loss. The use of such a conventional treatment is because, firstly, there are no known treatments related to hearing loss, and secondly, a large number of specialists and medicine industry workers are not clearly aware of the treatment for hearing loss. Due to these problems, the problem of inadequately performing treatment for hearing loss continues to arise.
특히, 항생제의 사용은 이독성을 가져 큰 문제점을 나타낸다. 예컨대, 아미노글리코사이드 항생제는 내이에서 청력과 평형 기능장애를 유발하는 이독성과 신장독성의 부작용을 가지고 있는데, 이는 과다복용뿐만 아니라 치료용량으로 장기간 복용시 발생할 수 있으며 일부에서는 단기간 적정용량에도 이독성이 발생하는 경우도 있다. 아미노글리코사이드 항생제 이독성은 사용자의 약 15%에서 전정기능 장애, 10-30%에서 청력감소를 보이며 주로 4000Hz 이상의 고주파수에서 급격한 고도난청의 형태로 양측 귀 모두에 발생한다.In particular, the use of antibiotics presents a major problem due to its toxicity. For example, aminoglycoside antibiotics have the side effects of toxic and nephrotoxicity that cause hearing and equilibrium dysfunction in the inner ear, which can occur not only in overdose but also in long-term doses as therapeutic doses, and in some cases even in short-term titration doses. This may occur. Aminoglycoside antibiotic toxicity is seen in both ears, with vestibular dysfunction in about 15% of users and hearing loss in 10-30%, mainly in the form of acute high hearing loss at high frequencies above 4000Hz.
이에 따라, 난청의 예방 및 치료에 효과적인 물질을 찾기 위한 연구로서 다양한 약물들에 대한 전임상 연구가 보고되고 있으나, 임상실험으로 진행하기에는 한계가 있음이 확인되었다. 또한, 현재까지 난청의 예방 및 치료와 관련하여 승인된 약물은 없다. 더욱이, 인체에 독성 또는 위험성 없이 사용할 수 있는 천연물 내지 천연 소재를 이용한 난청 치료제에 대해서는 개발된 약물을 거의 찾아볼 수 없다. 즉, 염증에 의해 유발되는 귀 관련 질환과 달리 난청에 대해 적합한 치료제가 전혀 개발되지 않은 실정이다. Accordingly, preclinical studies on various drugs have been reported as studies to find an effective substance for the prevention and treatment of hearing loss, but it has been confirmed that there is a limit to proceeding to clinical trials. In addition, there are no approved drugs to date for the prevention and treatment of hearing loss. Moreover, few drugs have been developed for the treatment of deafness using natural materials or natural materials that can be used without toxicity or danger to the human body. In other words, unlike ear-related diseases caused by inflammation, no suitable treatment for hearing loss has been developed.
이러한 배경 하에, 식품 또는 약제의 소재로 손쉽게 사용될 수 있는 소재를 이용하여 난청을 예방 또는 치료하기 위한 조성물에 관한 연구 개발이 절실히 필요한 실정이다. Under these circumstances, the research and development of a composition for preventing or treating hearing loss using a material that can be easily used as a material of food or drugs is urgently needed.
본 발명은 시지지움 큐미니 (Syzygium cumini) 추출물을 유효성분으로 포함하는 난청의 예방 또는 치료용 약학 조성물을 제공한다.The present invention is Sijigum Cumini ( Syzygium cumini ) Provides a pharmaceutical composition for the prevention or treatment of hearing loss comprising the extract as an active ingredient.
또한, 본 발명은 시지지움 큐미니 (Syzygium cumini) 추출물을 포함하는 난청의 예방 또는 개선용 식품 조성물을 제공한다.In addition, the present invention is Sijigum Cumini ( Syzygium cumini ) provides a food composition for preventing or improving hearing loss comprising the extract.
본 발명자들은 안전성이 우수한 천연 식물 소재를 대상으로 난청을 예방, 개선 및 치료할 수 있는 물질들을 찾기 위해 예의 노력한 결과, 놀랍게도 시지지움 큐미니 (Syzygium cumini) 추출물이 난청을 효과적으로 예방, 개선 및 치료함을 확인하고 본 발명을 완성하였다. The present inventors have made diligent efforts to find substances that can prevent, improve and treat hearing loss in natural plant materials with excellent safety. Surprisingly, Syzygium cumini extract effectively prevents, improves and treats hearing loss. It confirmed and completed this invention.
본 발명은 시지지움 큐미니 (Syzygium cumini) 추출물을 유효성분으로 포함하는 난청의 예방 또는 치료용 약학 조성물을 제공한다.The present invention is Sijigum Cumini ( Syzygium cumini ) Provides a pharmaceutical composition for the prevention or treatment of hearing loss comprising the extract as an active ingredient.
본 발명의 난청 예방 또는 치료용 약학 조성물은 난청으로 인한 청력 역치의 상승과 유모세포 손상을 효과적으로 억제시키는 작용 효과를 가짐으로써 난청에 우수한 치료 효과를 가진다. The pharmaceutical composition for preventing or treating hearing loss of the present invention has an excellent therapeutic effect on hearing loss by having an effect of effectively suppressing the increase of hearing threshold and hair cell damage caused by hearing loss.
본 발명에서 "난청(hearing loss)"이란 청각이 저하 또는 상실된 모든 상태를 의미한다. In the present invention, "hearing loss" means any state in which hearing is degraded or lost.
난청은 전음성 난청(conductive hearing loss) 및 감각신경성 난청(sensorineural hearing loss)을 포함한다. 여기서 상기 전음성 난청은 귀 질환에 의한 난청으로, 소리를 전달하는 기관인 고막과 이소골 등의 기관에 문제가 생겨 발생하는 난청이다. 감각신경성 난청은 소리를 감지하는 기관인 달팽이관과 전기적 에너지로 소리를 전달하는 청신경, 그리고 소리의 변별, 이해 등 종합적인 역할을 하는 청각을 담당하는 뇌에 문제가 생겨 발생하는 난청이다. 감각신경성 난청의 원인은 소음, 약물, 노화, 외상 등에 의해 발생하는 난청일 수 있고, 예컨대 이독성 난청일 수 있다. 상기 이독성 난청은 이독성 약물인 젠타마이신(gentamicin), 스트렙토마이신(streptomycin), 가나마이신(kanamycin), 네오마이신(neomycin), 아미카신(amikacin), 토브라마이신(tobramycin), 네틸마이신(netilmicin), 디베카신(dibekacin), 시소마이신(sisomycin), 리보도마이신(livodomycin), 시스플라틴(cisplatin), 카르보플라틴(carboplatin) 및 옥살리플라틴(oxaliplatin)으로 구성된 군으로부터 선택된 어느 하나 이상의 약물의 투여로 인한 난청일 수 있다. Hearing loss includes conductive hearing loss and sensorineural hearing loss. The pre-negative hearing loss is a hearing loss caused by the ear disease, the hearing loss caused by problems in the organs, such as the eardrum and bone bones that are organs that transmit sound. Sensorineural hearing loss is a hearing loss caused by problems in the cochlea, the organ that senses sound, the auditory nerve that delivers sound through electrical energy, and the brain, which plays a comprehensive role in the discrimination and understanding of sound. The cause of sensorineural hearing loss may be deafness caused by noise, drugs, aging, trauma, etc., for example, it may be toxic hearing loss. The toxic hearing loss is a toxic drug gentamicin (gentamicin), streptomycin (streptomycin), kanamycin (kanamycin), neomycin (neomycin), amikacin (amikacin), tobramycin, netylmycin ( Administration of any one or more drugs selected from the group consisting of netilmicin, dibekacin, sibeomycin, sisomycin, ribodomycin, cisplatin, carboplatin and oxaliplatin May be due to hearing loss.
또한 바람직하게 상기 난청은 소음성 난청, 노인성 난청, 돌발성 난청, 이독성 난청, 외상성 난청, 바이러스성 난청 등을 포함할 수 있으나, 청각이 저하 또는 상실된 상태에 해당한다면 본 발명의 위 난청의 범주에 제한되지 않고 질환 범위로 포함될 수 있다.In addition, the deafness may include noise deafness, senile deafness, sudden deafness, toxic deafness, traumatic deafness, viral deafness, and the like, but if the hearing is deteriorated or lost in the scope of the present invention deafness It is not limited and may be included in the disease range.
시지지움 큐미니 (Syzygium cumini)는 잠볼란, 자바 플럼, 블랙 플럼 등으로 흔히 알려져 있으며, 도금양과(Myrtaceae)에 속하는 식물이다. 주로, 동남아시아, 예컨대 베트남, 필리핀 등과 인도에서 서식하는 식물이다. 상기 시지지움 큐미니 (Syzygium cumini)의 추출 부위는 꽃, 전초, 잎, 줄기, 종자, 열매, 뿌리 등 식물체 부위에 제한받지 않으며 추출될 수 있다. Clear Message Queue Mini (Syzygium cumini ), commonly known as zambolan , Java plum, black plum, etc., is a plant belonging to the family Myrtaceae. Mainly, it is a plant which lives in Southeast Asia, such as Vietnam, Philippines, and India. The extraction site of the Syzygium cumini may be extracted without being limited to plant parts such as flowers, outposts, leaves, stems, seeds, fruits and roots.
상기 시지지움 큐미니 (Syzygium cumini) 추출물은 통상의 추출물 제조방법에 따라 시지지움 큐미니 (Syzygium cumini)로부터 추출되어 제조될 수 있다. 예를 들어, 시지지움 큐미니 (Syzygium cumini)의 무게에 대하여 약 1 내지 20 배, 바람직하게는 약 3 내지 10 배의 1차 추출용매, 바람직하게는 물, C1내지 C4의 저급알코올 (예컨대, 메탄올, 에탄올, 프로판올, 이소프로판올, 부탄올 등) 또는 이들의 혼합용매로 추출함으로써 수행할 수 있다. 추출은 당 분야에 알려진 추출방법, 예컨대, 냉침, 열수추출, 초음파 추출, 환류 냉각 추출 등의 방법으로 수행될 수 있으나, 이에 국한되지 않는다. 추출 온도는 당업자가 추출 방법에 적절한 다양한 온도 범위를 채택할 수 있으며, 예를 들어, 20 ℃ 내지 100 ℃ 등에서 수행될 수 있으나, 이에 국한되지 않는다. 또한, 추출시간은 추출방법에 따라 상이하며, 당업자가 적절한 추출시간을 채택할 수 있으며, 이에 국한되지 않으나, 약 1 시간 내지 10 일의 범위에서 단회 또는 복수회로 수행될 수 있다. 상기 1차 추출용매로 추출을 수행하여 얻어진 추출물은 통상의 방법에 따라 여과하여 불순물을 제거한 액상 형태로 얻거나, 얻어진 액상 형태의 추출물을 통상의 방법에 따라 감압농축 및/또는 건조하여 분말 형태로 얻을 수 있다. Sijigum Cumini ( Syzygium) cumini ) extract is Syzygium according to the conventional extract preparation method cumini ) can be extracted and prepared. For example, about 1 to 20 times, preferably about 3 to 10 times, the primary extractant, preferably water, C 1 to C 4 lower alcohols based on the weight of Syzygium cumini ( For example, methanol, ethanol, propanol, isopropanol, butanol and the like) or a mixed solvent thereof may be used for extraction. Extraction may be performed by an extraction method known in the art, such as cold soaking, hot water extraction, ultrasonic extraction, reflux cooling extraction, and the like, but is not limited thereto. The extraction temperature may be employed by those skilled in the art in various temperature ranges suitable for the extraction method, for example, may be carried out at 20 ℃ to 100 ℃ and the like, but is not limited thereto. In addition, the extraction time is different depending on the extraction method, a person skilled in the art can adopt an appropriate extraction time, but is not limited to this, it can be performed in a single or multiple times in the range of about 1 hour to 10 days. Extract obtained by performing extraction with the primary extraction solvent is obtained in a liquid form by removing impurities by filtration in accordance with a conventional method, or concentrated liquid extract and concentrated in a reduced pressure and / or dried in accordance with a conventional method in a powder form You can get it.
또한, 상기 추출공정은 필요에 따라, 유효성분의 함량이 높은 분획을 얻는 단계를 더 포함할 수 있다. 즉, 상기 1차 추출용매로 추출하여 얻어진 추출물을 물에 분산시킨 후, 적절한 2차 추출용매, 예컨대, 수포화 C1- C4 의 알코올로 추출하는 단계를 수행하여 유효성분의 함량을 증진시킬 수 있다. In addition, the extraction process may further comprise the step of obtaining a fraction having a high content of the active ingredient, if necessary. That is, the extract obtained by extracting with the primary extraction solvent is dispersed in water, followed by extraction with an appropriate secondary extraction solvent, for example, saturated C 1 -C 4 alcohol to enhance the content of the active ingredient. Can be.
본원 발명의 일실시양태에 따르면, 베트남 원산지의 Syzygium cumini (L.) Skeels을 메탄올로 추출하여 시지지움 큐미니 (Syzygium cumini) 메탄올 수용액 추출물을 제조하였다. 구체적으로, 시지지움 큐미니 (Syzygium cumini)의 전초를 80 %(v/v) 메탄올 추출물에서 1 시간동안 80 ℃에서 추출하여 제조하였다. According to one embodiment of the invention, Syzygium of Vietnamese origin cumini (L.) Syzygium by Extracting Skeels with Methanol cumini ) Methanol aqueous solution extract was prepared. Specifically, the outpost of Syzygium cumini was prepared by extracting at 80 ° C. for 1 hour in an 80% (v / v) methanol extract.
본 발명의 시지지움 큐미니 (Syzygium cumini) 추출물을 유효성분으로 함유하는 조성물의 총 중량에 대하여 0.1 내지 95 중량%로 시지지움 큐미니 (Syzygium cumini) 추출물을 포함하는 것이 바람직하나 이에 한정되지 않는다. Syzygium of the present invention cumini ) It is preferable to include the Syzygium cumini ( Sizygium cumini ) extract in an amount of 0.1 to 95% by weight based on the total weight of the composition containing the extract as an active ingredient, but is not limited thereto.
본 발명의 약학 조성물은 약제학적으로 허용가능한 담체를 포함할 수 있으며, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제제화될 수 있다.The pharmaceutical composition of the present invention may include a pharmaceutically acceptable carrier, and oral formulations, external preparations, suppositories, such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc., respectively, according to conventional methods. It may be formulated in the form of sterile injectable solutions.
상기 약제학적으로 허용가능한 담체는 당업계에서 통상적으로 사용되는 것들, 예컨대 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유 등을 포함하나 이에 국한되지 않는다. 또한, 본 발명의 약학 조성물은 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제, 기타 약제학적으로 허용가능한 첨가제를 포함한다.Such pharmaceutically acceptable carriers are those commonly used in the art, such as lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, Calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, and the like. In addition, the pharmaceutical compositions of the present invention include diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, surfactants, and other pharmaceutically acceptable additives.
본 발명의 약학 조성물이 경구용 고형 제제로 제제화된 경우 정제, 환제, 산제, 과립제, 캡슐제 등을 포함하며, 이러한 고형제제는 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트 (calcium carbonate), 수크로스(sucrose) 또는 락토즈, 젤라틴 등을 포함할 수 있으며, 마그네슘 스테아레이트, 탈크 같은 윤활제 등을 포함하나 이에 국한되지 않는다. When the pharmaceutical composition of the present invention is formulated as an oral solid preparation, it includes tablets, pills, powders, granules, capsules, and the like, and such solid preparations include at least one excipient such as starch, calcium carbonate, Sucrose or lactose, gelatin, and the like, and include, but are not limited to, lubricants such as magnesium stearate, talc, and the like.
본 발명의 약학 조성물이 경구용 액상 제제화된 경우 현탁제, 내용액제, 유제, 시럽제 등을 포함하며, 물, 리퀴드 파라핀 등의 희석제, 습윤제, 감미제, 방향제, 보존제 등을 포함하나 이에 국한되지 않는다. When the pharmaceutical composition of the present invention is formulated for oral liquid preparation, it includes a suspending agent, a liquid solution, an emulsion, a syrup, and the like, and includes, but is not limited to, diluents such as water and liquid paraffin, wetting agents, sweeteners, fragrances, preservatives, and the like.
본 발명의 약학 조성물이 비경구용 제제화된 경우 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제를 포함하며, 비수성 용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르류 등을 포함하나 이에 국한되지 않는다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈 (tween) 61, 카카오지, 라우린지, 글리세로젤라틴 등이 사용될 수 있으나 이에 국한되지 않는다.When the pharmaceutical composition of the present invention is formulated for parenteral use, it includes sterile aqueous solution, non-aqueous solvent, suspending agent, emulsion, lyophilized preparation, suppository, and the non-aqueous solvent, suspending agent is propylene glycol, polyethylene glycol, olive Vegetable oils such as oils, injectable esters such as ethyloleate, and the like. Bases of suppositories may include, but are not limited to, witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.
본 발명의 약학 조성물에 함유되는 시지지움 큐미니 (Syzygium cumini) 추출물의 투여량은 환자의 상태 및 체중, 연령, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 예를 들면, 시지지움 큐미니 (Syzygium cumini) 추출물은 1일 0.0001 내지 100 mg/kg으로, 바람직하게는 0.001 내지 10 mg/kg의 용량으로 투여할 수 있으며, 상기 투여는 하루에 한번 또는 수회 나누어 투여할 수도 있다. Syzygium contained in the pharmaceutical composition of the present invention The dosage of cumini ) extract depends on the patient's condition and weight, age, extent of disease, drug form, route of administration and duration, but may be appropriately selected by those skilled in the art. For example, Syzygium cumini extract may be administered at a dose of 0.0001 to 100 mg / kg, preferably 0.001 to 10 mg / kg, and the administration may be divided once or several times a day. It may also be administered.
본 발명의 약학조성물은 랫트, 마우스, 가축, 인간 등의 포유동물에 다양한 경로로, 예를 들면, 경구, 복강 또는 정맥, 근육, 피하, 자궁 내 경막 또는 뇌혈관 내 주사에 의해 투여될 수 있다. The pharmaceutical composition of the present invention can be administered to mammals such as rats, mice, livestock, humans, etc. by various routes, for example, by oral, intraperitoneal or intravenous, intramuscular, subcutaneous, intrauterine dural or cerebrovascular injections. .
본 발명은 또한 시지지움 큐미니 (Syzygium cumini) 추출물을 유효성분으로 포함하는 난청의 예방 또는 개선용 식품 조성물을 포함한다.The present invention is also referred to as Syzygium cumini ) includes a food composition for the prevention or improvement of hearing loss comprising the extract as an active ingredient.
본 발명의 식품 조성물은 건강기능식품으로서 사용될 수 있다. 상기 "건강기능식품"이라 함은 건강기능식품에 관한 법률에 따른 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 제조 및 가공한 식품을 의미하며, "기능성"이라 함은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건 용도에 유용한 효과를 얻을 목적으로 섭취하는 것을 의미한다.The food composition of the present invention can be used as a dietary supplement. The term "health functional food" means a food manufactured and processed using raw materials or ingredients having functional properties useful for the human body according to the law on health functional foods, and "functionality" refers to the structure and function of the human body. It means the ingestion for the purpose of obtaining a useful effect for health use such as nutrient control or physiological action.
본 발명의 식품 조성물은 통상의 식품 첨가물을 포함할 수 있으며, 상기 "식품 첨가물"로서의 적합 여부는 다른 규정이 없는 한, 식품의약품안전처에 승인된 식품 첨가물 공전의 총칙 및 일반시험법 등에 따라 해당 품목에 관한 규격 및 기준에 의하여 판정한다. The food composition of the present invention may include a conventional food additive, and the suitability as the "food additive" is applicable according to the General Regulations and General Test Method of the Food Additives approved by the Ministry of Food and Drug Safety unless otherwise specified. It is judged by the standard and the standard about the item.
상기 "식품 첨가물 공전"에 수재된 품목으로는 예를 들어, 케톤류, 글리신, 구연산칼륨, 니코틴산, 계피산 등의 화학적 합성물, 감색소, 감초추출물, 결정셀룰로오스, 고량색소, 구아검 등의 천연첨가물, L-글루타민산나트륨 제제, 면류첨가알칼리제, 보존료제제, 타르색소제제 등의 혼합제제류들을 들 수 있다.Examples of the items listed in the "Food Additive Revolution" include, for example, chemical compounds such as ketones, glycine, potassium citrate, nicotinic acid, and cinnamon acid, natural additives such as dark blue, licorice extract, crystalline cellulose, high pigment, guar gum, Mixed preparations, such as a sodium L- glutamate preparation, an alkali addition additive, a preservative preparation, and a tar pigment preparation, are mentioned.
본 발명의 식품 조성물은 조성물 총 중량에 대하여 시지지움 큐미니 (Syzygium cumini) 추출물을 0.01 내지 95 중량%, 바람직하게는 1 내지 80 중량%로 포함할 수 있다. 본 발명의 식품 조성물에 함유되는 시지지움 큐미니 (Syzygium cumini) 추출물은 상기 약학 조성물의 제조에서 언급된 추출방법과 동일한 방법으로 얻어질 수 있다. The food composition of the present invention may comprise 0.01 to 95% by weight of Syzygium cumini extract, preferably 1 to 80% by weight, based on the total weight of the composition. Syzygium cumini extract contained in the food composition of the present invention can be obtained by the same method as the extraction method mentioned in the preparation of the pharmaceutical composition.
또한, 본 발명의 식품 조성물은 난청의 예방 및/또는 개선을 목적으로, 정제, 캡슐, 분말, 과립, 액상, 환 등의 형태로 제조 및 가공할 수 있다.In addition, the food composition of the present invention may be prepared and processed in the form of tablets, capsules, powders, granules, liquids, pills and the like for the purpose of preventing and / or improving hearing loss.
예를 들어, 상기 정제 형태의 건강기능식품은 시지지움 큐미니 (Syzygium cumini) 추출물, 부형제, 결합제, 붕해제, 및 다른 첨가제와의 혼합물을 통상의 방법으로 과립화한 다음, 활택제 등을 넣어 압축성형하거나, 상기 혼합물을 직접 압축성형할 수 있다. 또한, 상기 정제 형태의 건강기능식품은 필요에 따라 교미제 등을 함유할 수 있으며, 필요에 따라 적당한 제피제로 제피할 수도 있다.For example, the dietary supplement in the form of tablets is a mixture of Syzygium cumini extract, excipients, binders, disintegrants, and other additives in a conventional manner, and then added with a lubricant, etc. Compression molding or the mixture may be compression molding directly. In addition, the health functional food in the form of tablets may contain a mating agent and the like, if necessary, may be coated with a suitable coating agent.
캡슐 형태의 건강기능식품 중 경질캡슐제는 통상의 경질캡슐에 시지지움 큐미니 (Syzygium cumini) 추출물, 및 부형제 등의 첨가제와의 혼합물 또는 그의 입상물 또는 제피한 입상물을 충진하여 제조할 수 있으며, 연질캡슐제는 시지지움 큐미니 (Syzygium cumini) 추출물 및 부형제 등의 첨가제와의 혼합물을 젤라틴 등 캡슐기제에 충진하여 제조할 수 있다. 상기 연질캡슐제는 필요에 따라 글리세린 또는 소르비톨 등의 가소제, 착색제, 보존제 등을 함유할 수 있다.Capsules of hard capsules of the dietary food queue mini (Syzygium Clear message to a conventional hard capsules cumini ) extract, and a mixture with additives such as excipients or granules or granulated products thereof may be filled, and soft capsules are mixed with additives such as Syzygium cumini extract and excipients. It can be prepared by filling in a capsule base such as gelatin. The soft capsule may contain a plasticizer such as glycerin or sorbitol, a colorant, a preservative, and the like, as necessary.
환 형태의 건강기능식품은 시지지움 큐미니 (Syzygium cumini) 추출물, 부형제, 결합제, 붕해제 등의 혼합물을 적당한 방법으로 성형하여 조제할 수 있으며, 필요에 따라 백당이나 다른 적당한 제피제로 제피를, 또는 전분, 탈크 또는 적당한 물질로 환의를 입힐 수도 있다.The dietary supplement in cyclic form is Syzygium cumini ) Mixtures of extracts, excipients, binders, disintegrants, etc. may be prepared by molding in a suitable manner, and may be coated with sucrose or other suitable coating agent, or may be starved with starch, talc or a suitable substance.
과립형태의 건강기능식품은 시지지움 큐미니 (Syzygium cumini) 추출물, 부형제, 결합제, 붕해제 등의 혼합물을 적당한 방법으로 입상으로 제조할 수 있으며, 필요에 따라 착향제, 교미제 등을 함유할 수 있다. 과립형태의 건강기능식품은 12호 (1680 μm), 14호 (1410 μm) 및 45호 (350 μm) 체를 써서 다음 입도시험을 할 때에 12호체를 전량 통과하고 14호체에 남는 것이 전체량의 5.0 %이하이고 또 45호체를 통과하는 것은 전체량의 15.0 %이하일 수 있다.The health functional food in the form of granules is Syzygium cumini ) Mixtures of extracts, excipients, binders, disintegrants and the like can be prepared into granules in a suitable manner, and may contain flavoring agents, copulating agents and the like as necessary. For the health functional food in the form of granules, No. 12 (1680 μm), No. 14 (1410 μm) and No. 45 (350 μm) were used for the next particle size test. Less than 5.0% and passing through the body 45 may be less than 15.0% of the total amount.
상기 부형제, 결합제, 붕해제, 활택제, 교미제, 착향제 등에 대한 용어 정의는 당업계에 공지된 문헌에 기재된 것으로 그 기능 등이 동일 내지 유사한 것들을 포함한다 (대한약전 해설편, 문성사, 한국약학대학협의회, 제 5 개정판, p33-48, 1989).The term definitions of the excipients, binders, disintegrants, glidants, copulation agents, flavoring agents and the like are described in the literature known in the art and include those having the same or similar functions (Korean Pharmacopoeia, Munseongsa, Korea Pharmacy University Council, 5th edition, pp. 33-48, 1989).
상기 식품의 종류에는 특별한 제한이 없다. 본 발명의 추출물을 첨가할 수 있는 식품의 예로는 음료, 껌, 비타민 복합제, 드링크제 등이 있으며, 통상적인 의미에서의 건강기능식품을 모두 포함한다.There is no particular limitation on the kind of food. Examples of foods to which the extract of the present invention may be added include beverages, gums, vitamin complexes, drinks, and the like, and include all health functional foods in a conventional sense.
본 발명은 시지지움 큐미니 (Syzygium cumini) 추출물을 대상체에 투여하는 단계를 포함하는 난청의 치료방법을 제공한다.The present invention is Sijigum Cumini ( Syzygium cumini ) provides a method for the treatment of hearing loss, comprising administering an extract to a subject.
본 발명에 "시지지움 큐미니 (Syzygium cumini) 추출물", "난청" 및 "투여" 등의 용어는 상기에서 설명한 바와 동일하다.In the present invention, "sijigum cumini ( Syzygium) cumini ) extract "," hearing loss "and" administration "and the like are the same as described above.
상기 대상체는 동물을 말하며, 전형적으로 본 발명의 시지지움 큐미니 (Syzygium cumini) 추출물을 이용한 치료로 유익한 효과를 나타낼 수 있는 포유동물일 수 있다. 이러한 대상체의 바람직한 예로 인간과 같은 영장류가 포함될 수 있다. 또한 이와 같은 대상체들에는 난청의 증상을 갖거나 이와 같은 증상을 가질 위험이 있는 대상체들이 모두 포함될 수 있다.The subject refers to an animal, and may be a mammal, which may typically have a beneficial effect with treatment with Syzygium cumini extract of the present invention. Preferred examples of such subjects may include primates, such as humans. In addition, such subjects may include all subjects having symptoms of or at risk of having such symptoms.
본 발명은 또한 난청의 치료를 위한 약제의 제조에서 상기 시지지움 큐미니 (Syzygium cumini) 추출물의 용도를 제공한다. The present invention also provides the use of said Syzygium cumini extract in the manufacture of a medicament for the treatment of hearing loss.
본 발명은 또한 난청의 치료에 사용하기 위한 상기 시지지움 큐미니 (Syzygium cumini) 추출물을 포함하는 조성물을 제공한다. The present invention also provides a composition comprising said Syzygium cumini extract for use in the treatment of hearing loss.
본 발명은 또한 난청의 치료를 위한 상기 시지지움 큐미니 (Syzygium cumini) 추출물의 용도를 제공한다. The present invention also provides the use of said Syzygium cumini extract for the treatment of hearing loss.
본 발명에 따른 시지지움 큐미니 (Syzygium cumini) 추출물은 난청으로 인한 청력 역치의 상승과 유모세포 손상을 효과적으로 억제시킴으로써 난청을 억제할 수 있어 난청의 예방 또는 치료에 유용하여, 약학 조성물 또는 건강기능식품으로써 유용하게 사용될 수 있다. Sijigum cumini ( Syzygium) according to the present invention cumini ) extract can suppress hearing loss by effectively suppressing hearing loss and hair cell damage caused by hearing loss, which can be useful for the prevention or treatment of hearing loss, and can be useful as a pharmaceutical composition or health food.
도 1은 시지지움 큐미니 (Syzygium cumini) 추출물을 네오마이신 처리에 의해 손상된 유모 세포에 처리하여 이의 예방, 치료 및 개선 효과를 확인한 결과를 나타낸다 (NOR: 네오마이신 미처리 정상 대조군, NM: 네오마이신 유도된 미처리 대조군, SCE: 시지지움 큐미니 (Syzygium cumini) 추출물 1 μg/mL 처리군 ).FIG. 1 shows the results of treatment of syzygium cumini extract on hair cells damaged by neomycin treatment to confirm its prevention, treatment and improvement (NOR: neomycin untreated normal control, NM: neomycin induction). Untreated control, SCE: Syzygium cumini extract 1 μg / mL treated group).
이하, 본 발명을 실시예를 통하여 더욱 상세히 설명한다. 그러나 이들 실시예 및 시험예는 본 발명을 예시하기 위한 것으로, 본 발명의 범위가 이들 실시예 및 시험예에 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to Examples. However, these Examples and Test Examples are for illustrating the present invention, and the scope of the present invention is not limited to these Examples and Test Examples.
실시예Example 1. One. 시지지움Sijium 큐미니Cumini ( ( SyzygiumSyzygium cuminicumini ) 추출물의 제조 ) Preparation of Extract
베트남 원산지의 Syzygium cumini (L.) Skeels 80 % (v/v) 메탄올 추출물은 한국생명공학연구원 해외생물소재센터에서 분양받았으며, 표본시료는 해외생물소재센터에 보관되어 있다. Syzygium of Vietnamese origin cumini (L.) Skeels 80% (v / v) Methanol extract was distributed at the Korea Institute of Bioscience and Biotechnology, Overseas Biomaterials Center.
위 Syzygium cumini (L.) Skeels 80 % (v/v) 메탄올 추출물은 상기 시지지움 큐미니 (L.) Skeels (Syzygium cumini (L.) Skeels)의 전초 부위를 80 %(v/v) 메탄올에 1 시간 동안 80℃ 온도로 추출한 것이다. 이 과정을 1 회 반복하여 추출물을 제조한 후, 55℃ 온도에서 감압농축기로 농축한 후, 동결건조하여 시지지움 큐미니 (Syzygium cumini)의 메탄올 추출물이 최종 제조되었다. Stomach Syzygium cumini (L.) Skeels 80% (v / v) Methanol extracts are used for the cizium cumin (L.) Skeels ( Syzygium cumini (L.) Skeels) were extracted from 80% (v / v) methanol at 80 ° C for 1 hour. This process was repeated once to prepare an extract, and then concentrated in a vacuum condenser at 55 ℃ temperature, and then lyophilized to obtain a methanol extract of Syzygium cumini (final).
실시예Example 2. 2. 이독성Toxicity 제브라피시Zebrafish 모델에서 In the model 시지지움Sijium 큐미니Cumini ( ( SyzygiumSyzygium cuminicumini ) 추출물의 유모세포 보호효과 Effect of Extracts on Hair Cells
실시예 1 시지지움 큐미니 (Syzygium cumini) 추출물을 네오마이신에 의해 감소된 유모세포에 처리하여 이의 유모 세포 보호 효과를 확인하였다. Example 1 Syzygium cumini ) extract was treated with hair cells reduced by neomycin to confirm its hair cell protective effect.
구체적으로, 수정 6일 후(6 day post fertilization)의 제브라피시 치어(zebrafish larvae)를 24 웰에 위치시켜 2 μM 네오마이신에 1시간 노출시켰다. 이후, 실시예 1의 시지지움 큐미니 (Syzygium cumini) 추출물 1 μg/mL로 교체하여 6시간 동안 노출시켰으며, 대조군으로써 0.03% 해수염 용액(sea salt solution)을 처리하였다. 직접적인 유모세포의 관찰을 위해 형광현미경(Olympus 1×70, Olympus, Japan)을 사용하였으며, 0.1% YO-PRO로 30분 동안 염색하였다. 제브라피시 치어를 0.02% 트리카인으로 마취시키고, 유모세포를 형광현미경으로 관찰하였다. 형광현미경을 통해 획득한 유모세포의 개수를 세어 데이터를 분석하였다. Specifically, zebrafish larvae 6 days post fertilization (6 day post fertilization) were placed in 24 wells for 1 hour exposure to 2 μM neomycin. Thereafter, it was exposed for 6 hours by replacing 1 μg / mL of Syzygium cumini extract of Example 1, and treated with 0.03% sea salt solution as a control. Fluorescence microscopy (Olympus 1 × 70, Olympus, Japan) was used for direct observation of hair cells, and stained with 0.1% YO-PRO for 30 minutes. Zebrafish cheers were anesthetized with 0.02% tricaine and hair cells were observed by fluorescence microscopy. The data was analyzed by counting the number of hair cells obtained through a fluorescence microscope.
그 결과를 도 1에 나타내었다. The results are shown in FIG.
도 1에서 확인되는 바와 같이, 시지지움 큐미니 (Syzygium cumini) 추출물이 처리된 실험군에서 유모세포의 개수가 유의적으로 증가한 것이 확인되며, 이를 통해서 본원 발명에 따른 시지지움 큐미니 (Syzygium cumini) 추출물이 난청의 예방, 개선 및 치료에 우수한 효과가 있음이 확인되었다. As confirmed in FIG. 1, Syzygium cimini cumini ) It was confirmed that the number of hair cells significantly increased in the experimental group treated with extract, through which the Syzygium cumini extract according to the present invention has an excellent effect on the prevention, improvement and treatment of hearing loss. Confirmed.
[[ 제제예Formulation example ]]
실시예 1의 시지지움 큐미니 (Syzygium cumini) 추출물을 사용하여 아래와 같은 제형을 제조하였다. 그러나, 하기 제제예는 본 발명을 예시하는 것일 뿐, 이에 의해 본 발명의 내용이 제한되는 것은 아니다. Syzygium of Example 1 cumini ) to prepare the following formulation using the extract. However, the following formulation examples are merely illustrative of the present invention, whereby the content of the present invention is not limited.
제제예Formulation example 1. 정제의 제조 1. Preparation of Tablets
시지지움 큐미니 (Syzygium cumini) 추출물.................1000 ㎎Clear Message Queue Mini (Syzygium cumini ) extract .................. 1000 mg
유당 .....................................................100 ㎎Lactose ... .... 100 mg
전분 .....................................................100 ㎎Starch ..................... .... 100 mg
스테아린산 마그네슘 ........................................적량Magnesium Stearate ...............
통상의 정제 제조방법에 따라 상기의 성분을 혼합하고 타정하여 정제를 제조하였다.Tablets were prepared by mixing and tableting the above components according to a conventional tablet production method.
제제예Formulation example 2. 2. 액제의Liquid 제조 Produce
시지지움 큐미니 (Syzygium cumini) 추출물.................1000 ㎎Clear Message Queue Mini (Syzygium cumini ) extract .................. 1000 mg
CMC-Na......................................................20 gCMC-Na ............ ....... 20 g
이성화당....................................................20 gIsomerized sugar ... .... 20 g
레몬향......................................................적량Lemon flavor ...... suitable
정제수를 가하여 전체 1000 ㎖로 맞추었다. 통상의 액제의 제조방법에 따라 상기의 성분을 혼합한 다음, 갈색병에 충전하고 멸균시켜 액제를 제조하였다.Purified water was added to adjust the total volume to 1000 ml. According to the conventional method for preparing a liquid, the above components were mixed, and then filled into a brown bottle and sterilized to prepare a liquid.
제제예Formulation example 3. 캡슐제의 제조 3. Preparation of Capsule
시지지움 큐미니 (Syzygium cumini) 추출물.................1000 ㎎Clear Message Queue Mini (Syzygium cumini ) extract .................. 1000 mg
결정성 셀룰로오스...........................................3 ㎎Crystalline Cellulose ......................................... 3 mg
락토오스.................................................14.8 ㎎Lactose ... 14.8 mg
마그네슘 스테아레이트.....................................0.2 ㎎Magnesium Stearate ... 0.2 mg
통상의 캡슐제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.According to a conventional capsule preparation method, the above ingredients were mixed and filled into gelatin capsules to prepare capsules.
제제예Formulation example 4. 주사제의 제조 4. Preparation of Injectables
시지지움 큐미니 (Syzygium cumini) 추출물.................1000 ㎎Clear Message Queue Mini (Syzygium cumini ) extract .................. 1000 mg
만니톨....................................................180 ㎎Mannitol ... ... 180 mg
주사용 멸균 증류수.......................................2974 ㎎Sterile Distilled Water for Injection ............... 2974 mg
Na2HPO412H2O................................................26 ㎎Na 2 HPO 4 12H 2 O ........................................... ..... 26 mg
통상의 주사제의 제조방법에 따라 1 앰플당 (2 ㎖) 상기의 성분 함량으로 제조하였다. According to the conventional method for preparing an injection, the amount of the above ingredient was prepared per ampoule (2 ml).
제제예Formulation example 5. 건강기능성 음료의 제조 5. Preparation of Health Functional Beverages
시지지움 큐미니 (Syzygium cumini) 추출물 ..................... 100 mgClear Message Queue Mini (Syzygium cumini ) Extract ..................... 100 mg
구연산 ...................................................... 1000 mgCitric Acid ... ..... 1000 mg
올리고당 .................................................... 100 goligosaccharide ................................................. ... 100 g
매실농축액 ..................................................... 2 gPlum Concentrate ... ..... 2 g
정제수를 가하여 전체 ........................................ 900 mLPurified water is added to the total ..................... 900 mL
통상의 건강기능성 음료 제조방법에 따라 상기의 성분을 혼합하여 건강 기능성 음료를 제조하였다. According to the conventional method for preparing a health functional beverage, the above components were mixed to prepare a health functional beverage.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170174390A KR102075694B1 (en) | 2017-12-18 | 2017-12-18 | Composition for preventing or treating hearing loss comprising Syzygium cumini extracts |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170174390A KR102075694B1 (en) | 2017-12-18 | 2017-12-18 | Composition for preventing or treating hearing loss comprising Syzygium cumini extracts |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20190073082A KR20190073082A (en) | 2019-06-26 |
KR102075694B1 true KR102075694B1 (en) | 2020-02-10 |
Family
ID=67105259
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020170174390A KR102075694B1 (en) | 2017-12-18 | 2017-12-18 | Composition for preventing or treating hearing loss comprising Syzygium cumini extracts |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102075694B1 (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2011000862A (en) | 2008-07-21 | 2011-03-15 | Otonomy Inc | Controlled release antimicrobial compositions and methods for the treatment of otic disorders. |
PL2366408T3 (en) | 2010-03-01 | 2013-01-31 | Salvat Lab Sa | Aqueous clear solutions of fluocinolone acetonide for treatment of otic inflammation |
-
2017
- 2017-12-18 KR KR1020170174390A patent/KR102075694B1/en active IP Right Grant
Non-Patent Citations (2)
Title |
---|
Clin. Microbiol. Infect., 2005, 11, pp.559-563.* |
Pharmacogn. J., 2017, 9(6), Suppl: s122-s128.* |
Also Published As
Publication number | Publication date |
---|---|
KR20190073082A (en) | 2019-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Asgarpanah et al. | Chemistry, pharmacology and medicinal properties of Peganum harmala L | |
Rajvaidhya et al. | A review on Acacia arabica-an Indian medicinal plant | |
KR101288053B1 (en) | Composition for Prevention or Treatment of inner ear damage Comprising an extract of Piper longum L. | |
CN105709105A (en) | Composition with function of clearing peculiar smell in oral cavity and preparation method of composition | |
EP2293805B1 (en) | Lozenge composition for treating inflammatory diseases of the mouth and pharynx | |
KR20120038372A (en) | Extract of angelica gigas nakai, ginkgo biloba l. leaves; or composition comprising extract of angelica gigas nakai and ginkgo biloba l. leaves for alzheimer's disease adjuvant or the pharmaceutical composition for the treatment of alzheimer's disease | |
KR102094228B1 (en) | Composition for preventing or treating hearing loss comprising Uncaria rhynchophylla extracts | |
KR20220099175A (en) | Oral composition comprising herbal complex | |
KR20160081359A (en) | A pharmaceutical composition for treating or preventing respiratory disease comprising combined herbal extracts | |
KR102099363B1 (en) | Pharmaceutical composition for preventing or treating comprising avocado oil fraction as an active ingredient | |
KR102206882B1 (en) | Composition for preventing or treating hearing loss comprising extract of leaves or stem of sweet potato | |
KR102075694B1 (en) | Composition for preventing or treating hearing loss comprising Syzygium cumini extracts | |
KR101989739B1 (en) | Composition for preventing or treating diabetes mellitus comprising Rorippa globosa extracts | |
JP2014208620A (en) | Anti-obesity agent | |
KR102007096B1 (en) | Composition for preventing or treating hearing loss comprising Viscum ovalifolium extracts | |
KR102323400B1 (en) | Combined Composition for preventing or treating hearing loss comprising Sarpogrelate and Vaccinium myrtillus extract | |
KR102030123B1 (en) | Composition for preventing or treating hearing loss | |
KR102028383B1 (en) | Composition for preventing or treating hearing loss | |
KR102035845B1 (en) | Composition for preventing or treating hearing loss | |
KR102131044B1 (en) | Composition for preventing or treating hearing loss | |
KR101945635B1 (en) | Composition for preventing or treating hearing loss | |
KR102313249B1 (en) | Composition for preventing or treating hearing loss comprising extract or fraction of Castanopsis echinocarpa | |
US20220401508A1 (en) | Composition comprising sweet potato stem or leaf extract as active ingredient for prevention or treatment of ear disease | |
KR20200085222A (en) | Composition for preventing or treating hearing loss comprising Spirulina maxima extracts | |
JPH08151329A (en) | Antiviral agent, carcinostatic agent and production thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
G170 | Publication of correction |